Annual report pursuant to Section 13 and 15(d)

License and Contract Revenue (Details)

v3.20.4
License and Contract Revenue (Details)
$ in Thousands, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 17, 2020
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
CAD ($)
Dec. 31, 2010
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenues   $ 50,030 $ 29 $ 29 $ 30 $ 29 $ 230 $ 29 $ 30 $ 50,118 $ 318 $ 463    
Licensing revenue                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenues                   50,118 318 118    
Contract revenue                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenues                   0 0 345    
3SBio Inc. | Licensing revenue                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Revenues                   118 118 118    
Deferred revenue   $ 207       $ 324       $ 207 324 442    
Merck Animal Health | Licensing revenue                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Upfront payments received                     200      
Revenues                     $ 200      
Hepion Pharmaceuticals, Inc. | Contract revenue                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Upfront payments received                       $ 345 $ 450,000  
License Agreement Terms | Otuska                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Upfront payments received $ 50,000                          
Potential regulatory milestone revenue 50,000                          
Revenues $ 50,000                          
License Agreement Terms | Otuska | Minimum                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Tiered royalty percentages on future sales 10.00%                          
License Agreement Terms | Otuska | Maximum                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Tiered royalty percentages on future sales 20.00%                          
License Agreement Terms | 3SBio Inc.                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                            
Upfront payments received                           $ 1,500